Jaguar Health Induces Bold Hires with Nasdaq-Approved Grants: A Step Closer to the Future!

Jaguar Health Inc. (NASDAQ:JAGX) recently granted two new employees a combined total of 4,100 restricted stock units (RSUs). New Employee 1 was granted 100 RSUs, while New Employee 2 received a whopping 4,000!

These RSUs will vest equally over three years, with one-third of the shares vesting each year starting from their respective dates of hire. This generous gift provides the new employees with a great opportunity to share in the Company’s future success.

The Company, with the approval of its Compensation Committee of the Board, granted Restricted Stock Units (RSUs) to each new employee as an incentive to accept employment. These RSUs will vest over time, provided the employee remains employed with Jaguar until their applicable vesting date.

About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health

Jaguar Health, Inc. is revolutionizing the pharmaceutical industry with their plant-based, sustainably derived prescription medicines for people and animals. Their wholly owned subsidiary, Napo Pharmaceuticals, Inc., is currently conducting an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.

Additionally, Jaguar Health established an Italian corporation, Napo Therapeutics S.p.A., to expand crofelemer access in Europe. Through their cutting-edge research, Jaguar Health is leading the way in providing innovative and effective treatments for those suffering from GI distress and chronic, debilitating diarrhea.

Leave a Comment